Clene AI Stock Analysis
Clene (84C0) AI Stock Analysis
Clene
(Frankfurt:84C0)
No summary available
Clene (84C0) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 50.69M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -1.5
- Beta (1Y)
- 0.75
- Revenue Growth
- 3.08%
- EPS Growth
- 34.10%
- Country
- Germany
- Employees
- 78
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Biotechnology
Clene Business Overview & Revenue Model
Company Description
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship...
Clene Risk Analysis
Clene disclosed 66 risk factors in its most recent earnings report. Clene reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksClene Peers Comparison
Overall Rating
GANX54Neutral
CGTX42Neutral
NRXS42Neutral
ANVS39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 54Neutral | $46.75M | -2.38 | -133.17% | ― | ― | 33.17% | |
| 42Neutral | $57.12M | -3.45 | -50.57% | ― | ― | 62.99% | |
| 42Neutral | $63.87M | -4.02 | -252.10% | ― | 94.29% | -4.03% | |
| 39Underperform | $46.42M | -0.43 | -8312.82% | ― | ― | -15.00% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:84C0 | Clene Inc | 3.04 | -4.81 | -61.27% | |
| ANVS | Annovis Bio Inc | 0.71 | -3.38 | -82.62% | |
| GANX | Gain Therapeutics, Inc. | 1.00 | -1.83 | -64.70% | |
| CGTX | Cognition Therapeutics, Inc. | 0.58 | -0.95 | -61.96% | |
| NRXS | NeurAxis, Inc. | 4.22 | 1.64 | 63.57% | |
| PLYX | Polaryx Therapeutics, Inc. | 1.33 | -33.67 | -96.20% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
